ABMD:NSD-Abiomed, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 337.59

Change

+6.99 (+2.11)%

Market Cap

USD 14.95B

Volume

0.25M

Average Target Price

USD 320.60 (-5.03%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+11.30 (+1.90%)

USD47.08B 26.55 95.73
PODD Insulet Corporation

+10.18 (+3.58%)

USD18.81B 2,847.00 173.03
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.34 (+0.50%)

USD10.24B 66.21 33.00
IART Integra LifeSciences Holdings ..

+0.73 (+1.04%)

USD5.93B 44.73 25.09
TNDM Tandem Diabetes Care, Inc

+5.12 (+5.93%)

USD5.40B N/A N/A
SWAV ShockWave Medical, Inc

+2.03 (+1.47%)

USD4.93B N/A N/A
LIVN LivaNova PLC

+1.41 (+1.73%)

USD3.99B 77.40 N/A
SDC SmileDirectClub, Inc

-0.07 (-0.67%)

USD3.95B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing ABMD

Symbol Name Weight Mer Price(Change) Market Cap
CHEP AGFiQ U.S. Market Neutral.. 0.00 % 1.42 %

N/A

USD0.75M
MOM AGFiQ U.S. Market Neutral.. 0.00 % 2.58 %

N/A

USD4.73M
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

+4.47 (+1.63%)

USD0.78B
SLIM The Obesity ETF 0.00 % 0.35 %

N/A

USD0.01B
XHE SPDR S&P Health Care .. 0.00 % 0.35 %

+1.55 (+1.27%)

USD0.79B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.13% 30% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.13% 30% F 42% F
Trailing 12 Months  
Capital Gain 110.73% 63% D 72% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.73% 63% D 71% C-
Trailing 5 Years  
Capital Gain 243.71% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 243.71% 85% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 43.36% 78% C+ 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.36% 78% C+ 85% B
Risk Return Profile  
Volatility (Standard Deviation) 70.68% 37% F 22% F
Risk Adjusted Return 61.35% 87% B+ 79% C+
Market Capitalization 14.95B 98% A+ 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 75.36 21% F 16% F
Price/Book Ratio 11.97 29% F 15% F
Price / Cash Flow Ratio 47.48 12% F 10% F
EV/EBITDA 58.90 43% F 18% F
Management Effectiveness  
Return on Equity 17.37% 95% A 88% B+
Return on Invested Capital 19.52% 94% A 91% A-
Return on Assets 10.82% 95% A 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.95 45% F 28% F
Short Percent 3.00% 68% D+ 54% F
Beta 1.31 41% F 40% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.